The MamaMiso study of self-administered misoprostol to prevent bleeding after childbirth in rural Uganda: a community-based, placebo-controlled randomised trial
Authors:
- Andrew D. WeeksAWAndrew D. Weeks
- James DitaiJDJames Ditai
- Sam OnongeSOSam Ononge
- Brian FaragherBFBrian Faragher
- Laura J. FryeLFLaura J. Frye
- Jill DurocherJDJill Durocher
- Florence M. MirembeFMFlorence M. Mirembe
- Josaphat ByamugishaJBJosaphat Byamugisha
- Beverly WinikoffBWBeverly Winikoff
- Zarko AlfirevicZAZarko Alfirevic
Open Access
- 14 September 2015
- journal article
- research article
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 15 (1) , 1-10
Abstract
600 mcg of oral misoprostol reduces the incidence of postpartum haemorrhage (PPH), but in previous research this medication has been administered by health workers. It is unclear whether it is also safe and effective when self-administered by women. This placebo-controlled, double-blind randomised trial enrolled consenting women of at least 34 weeks gestation, recruited over a 2-month period in Mbale District, Eastern Uganda. Participants had their haemoglobin measured antenatally and were given either 600mcg misoprostol or placebo to take home and use immediately after birth in the event of delivery at home. The primary clinical outcome was the incidence of fall in haemoglobin of over 20 % in home births followed-up within 5 days. 748 women were randomised to either misoprostol (374) or placebo (374). Of those enrolled, 57 % delivered at a health facility and 43 % delivered at home. 82 % of all medicine packs were retrieved at postnatal follow-up and 97 % of women delivering at home reported self-administration of the medicine. Two women in the misoprostol group took the study medication antenatally without adverse effects. There was no significant difference between the study groups in the drop of maternal haemoglobin by >20 % (misoprostol 9.4 % vs placebo 7.5 %, risk ratio 1.11, 95 % confidence interval 0.717 to 1.719). There was significantly more fever and shivering in the misoprostol group, but women found the medication highly acceptable. This study has shown that antenatally distributed, self-administered misoprostol can be appropriately taken by study participants. The rarity of the primary outcome means that a very large sample size would be required to demonstrate clinical effectiveness. This study was registered with the ISRCTN Register ( ISRCTN70408620 ).Keywords
This publication has 17 references indexed in Scilit:
- Global causes of maternal death: a WHO systematic analysisThe Lancet Global Health, 2014
- Misoprostol for postpartum hemorrhage prevention at home birth: an integrative review of global implementation experience to dateBMC Pregnancy and Childbirth, 2013
- Should oral misoprostol be used to prevent postpartum haemorrhage in home‐birth settings in low‐resource countries? A systematic review of the evidenceBJOG: An International Journal of Obstetrics & Gynaecology, 2012
- Advance misoprostol distribution for preventing and treating postpartum haemorrhageCochrane Database of Systematic Reviews, 2012
- Administration of misoprostol by trained traditional birth attendants to prevent postpartum haemorrhage in homebirths in Pakistan: a randomised placebo-controlled trialBJOG: An International Journal of Obstetrics & Gynaecology, 2010
- Expanding uterotonic protection following childbirth through community‐based distribution of misoprostol: Operations research study in NepalInternational Journal of Gynecology & Obstetrics, 2010
- Prevention of postpartum hemorrhage at home birth in AfghanistanInternational Journal of Gynecology & Obstetrics, 2010
- Oral misoprostol in preventing postpartum haemorrhage in resource-poor communities: a randomised controlled trialThe Lancet, 2006
- Effect of sublingual misoprostol on severe postpartum haemorrhage in a primary health centre in Guinea-Bissau: randomised double blind clinical trialBMJ, 2005
- Misoprostol in the management of the third stage of labour in the home delivery setting in rural Gambia: a randomised controlled trialBJOG: An International Journal of Obstetrics & Gynaecology, 2005